The following antibodies were used in this study: anti-PEN-2 antibody (a gift from Dr. Thinakaran), anti-V5 antibody (Invitrogen), anti-PS1 N-terminal antibody (Ab14), anti-Myc antibody (Invitrogen), anti-APP C-terminal antibody against the residues 676–695 of APP695 (Sigma), anti-APP N-terminal antibody against the residues 99–126 of APP (Chemicon), anti-APP C-terminal antibody 6E10 (Signet), anti-APH-1–1 antibody, anti-nicastrin antibody (Sigma), anti-calnexin antibody (Transduction Laboratories), and anti-GM130 antibody (Transduction Laboratories). The Ab ELISA studies used antibodies JRF/cAb40/10, JRF/cAb42/26, and JRF/Abtot/1, which were gifts from Dr. Marc Mercken (Johnson and Johnson Pharmaceutical Research and Development/Janssen Pharmaceutica, Beerse, Belgium). Anti-V5 or anti-PEN-2 antibodies were used for immunoblotting.